Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Sydney’s EnGeneIC Raises Funds in Singapore for Targeted Nanocell Technology

publication date: Jun 10, 2024

Australia’s EnGeneIC, a company developing a targeted nanocell technology for cancer therapies, announced financial partnerships with two Singapore entities, Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI). Although the investment amount was not disclosed, the financing was called “significant.” The funding will be used to advance EnGeneIC’s proprietary technology, EnGeneIC Dream Vector, for oncology and infectious diseases. The first-in-class EDVTM nanocell is the basis of an antibody nanocell drug conjugate platform for delivering therapeutic payloads -- drugs, siRNAs, miRNAs, adjuvants – via antibody-targeting of a cancer cell’s surface with minimal toxicity. More details....

Share this with colleagues:  

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital